|
|
The result analyzing of treatment superficial gastritis patients by Rebamipide combined with Rabeprazole |
HUANG Jia-min1 HUANG Zhi-xiong2 |
1.Department of Pharmacy,Shunde Hospital of Southern Medical University,Guangdong Province,Foshan 528300,China;
2.Department of Gastroenterology,Shunde Hospital of Southern Medical University,Guangdong Province,Foshan 528300,China |
|
|
Abstract Objective To approach result of treatment superficial gastritis patients by Rebamipide combined with Rabeprazole.Methods The 200 cases clinical data of diagnosising and treat superficial gastritis patients in our hospital outpatient service from January 2016 to July 2017 were analyzed,which were divided into two group by different treatment method,which were control group (Rabeprazole treatment,100 cases)and detection group (Rebamipide combined with Rabeprazole treatment,100 cases).The IL-2,IL-4,IL-8,TGF-β,IL-17,IL-25,SOD,MDA levels of two group patients before treatment and after treatment were detected,the clinical treatment total effects rate of two group patients were detected.Results The IL-2,IL-4,IL-8,TGF-β,IL-17,IL-25,SOD,MDA levels of two group patients before treatment were no difference (P>0.05),the IL-2,SOD of two group after treatment were higher than before treatment,IL-4,IL-8,TGF-,IL-17,IL-25,MDA levels were lower than before treatment,the IL-2,SOD of detection group after treatment were higher than control group,IL-4,IL-8,TGF-β,IL-17,IL-25,MDA levels were lower than control group,the clinical treatment total effects rate of detection group was higher than control group,the differences were statistical significance(P<0.05).Conclusion The treatment superficial gastritis patients by Rebamipide combined with Rabeprazole,which could improve inflammatory indicators,the result is good,it is worth to be used.
|
|
|
|
|
[1] |
李焕杰,高峰玉.雷贝拉唑钠肠溶片治疗老年浅表性胃炎的临床研究[J].中国临床药理学杂志,2017,33(11):986-988.
|
[2] |
Qin F,Liu JY,Yuan JH.Chaihu-Shugan-San.an oriental herbal preparation,for the treatment of chronic gastritis:a metaanalysis of randomized controlled trials[J].J Ethopharmacol,2013,146(2):433-439.
|
[3] |
叶纪纲.雷贝拉唑联合曲美布汀治疗慢性浅表性胃炎的临床疗效观察[J].海峡药学,2017,29(2):215-216.
|
[4] |
Wu Y,Fan Y,Jiang Y,et al.Analysis of risk factors associated withprecancerouslesionofgastriccancerinpatientsfromeastern China:a comparative study[J].J Cancer Res Ther,2013,9(2):205-209.
|
[5] |
吴玩忠,吴志勇,江杰生.瑞巴派特联合雷贝拉唑三联疗法治疗Hp感染相关性消化性溃疡的效果观察[J].中国医药科学,2017,7(21):202-204.
|
[6] |
Tu H,Sun L,Dong X,et al.Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis,mucosal bacterial density,and levels of serum biomarkers[J].Scand J Gastroenterol,2014,49(3):259-266.
|
[7] |
朱晨宇,杨振华.瑞巴派特三联疗法用于胃溃疡伴胃出血的临床观察[J].中国药房,2017,28(6):766-769.
|
[8] |
杨泽民,陈蔚文,王颖芳.慢性浅表性胃炎脾虚证患者与健康人物质能量代谢基因差异表达研究[J].中国中西医结合杂志,2013,33(2):159-163.
|
[9] |
李焕杰,高峰玉.雷贝拉唑钠肠溶片治疗老年浅表性胃炎的临床研究[J].中国临床药理学杂志,2017,33(11):986-988.
|
[10] |
Tortora R,Imperatore N,Capone P,et al.The presence of antiendomysial antibodies and the level of anti tissue transglutaminases can be used to diagnose adult coeliac disease without duodenal biopsy[J].Aliment Pharmacol Ther,2014,40(10):1223-1229.
|
[11] |
王金鑫.幽门螺杆菌感染及非甾体抗炎药致消化性溃疡并发出血的相关性研究[J].中国医师进修杂志,2014,37(7):25-27.
|
[12] |
Yu XW,Xu Q,Xu Y,et al.Expression of the E-cadherin/β-catenin/tcf-4 pathway in gastric diseases with relation to Helicobacter pylori infection:clinical and pathological implications[J].Asian Pac J Cancer Prev,2014,15(1):215-220.
|
[13] |
彭廷勇,何熙国,周琮凯,等.序贯疗法治疗幽门螺杆菌阳性消化性溃疡的疗效观察及安全性分析[J].实用医院临床杂志,2017,14(2):88-90.
|
[14] |
Wang TR,Peng JC,Qiao YQ,et al.Helicobacter pylori regulates TLR4 and TLR9 during gastric carcinogenesis[J].Int J Clin Exp Pathol,2014,7(10):6950-6955.
|
[15] |
张艳莉.检测血清胃泌素、转化生长因子-α和超敏C-反应蛋白在幽门螺杆菌阳性消化性溃疡临床诊断及判断预后中的临床意义[J].中国临床医生杂志,2017,45(2):61-63.
|
[16] |
Yu Y,Su L,Wang X,et al.Association between Helicobacter pylori infection and pathological changes in the gastric mucosa in Chinese children[J].Intern Med,2014,53(2):83-88.
|
|
|
|